JAK inhibitors and black box warnings: what is the future for JAK inhibitors?
JAK inhibitors and black box warnings: what is the future for JAK inhibitors? Expert Rev Clin Immunol. 2023 Jul-Dec; 19(11):1385-1397.
PMID: 37596779
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors.
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors. Drug Saf. 2023 Nov; 46(11):1049-1071.
PMID: 37490213
Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis.
Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis. Respir Med. 2023 Oct; 217:107330.
PMID: 37385460
Anticitrullinated peptide antibody epitope expansion and the HLA DRB1 'shared epitope' are less common in seropositive checkpoint inhibitor-induced inflammatory arthritis than in longstanding rheumatoid arthritis.
Anticitrullinated peptide antibody epitope expansion and the HLA DRB1 'shared epitope' are less common in seropositive checkpoint inhibitor-induced inflammatory arthritis than in longstanding rheumatoid arthritis. RMD Open. 2023 Jun; 9(2).
PMID: 37355249
Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.
Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events. Oncologist. 2023 05 08; 28(5):440-448.
PMID: 36595378
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events.
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events. JAMA Oncol. 2023 05 01; 9(5):723-724.
PMID: 36892846
Role-Specific Curricular Needs for Identification and Management of Immune-Related Adverse Events.
Role-Specific Curricular Needs for Identification and Management of Immune-Related Adverse Events. J Cancer Educ. 2023 10; 38(5):1486-1492.
PMID: 37022615
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis.
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis. 2023 07; 82(7):920-926.
PMID: 37019614
Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics.
Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics. Pharmaceuticals (Basel). 2023 Feb 08; 16(2).
PMID: 37259404
Treatment of rheumatic adverse events of cancer immunotherapy.
Treatment of rheumatic adverse events of cancer immunotherapy. Best Pract Res Clin Rheumatol. 2022 12; 36(4):101805.
PMID: 36539321